Holen Sie sich die Stockscreener-App
27.38
0.11%
0.03
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Will Celldex Therapeutics Inc. stock see insider buyingPortfolio Risk Summary & Detailed Earnings Play Strategies - ulpravda.ru
Will Celldex Therapeutics Inc. stock deliver better than expected guidanceQuarterly Profit Report & Advanced Swing Trade Entry Plans - ulpravda.ru
Why Celldex Therapeutics Inc. (TCE2) stock could be top winnerJuly 2025 Chart Watch & Fast Entry High Yield Tips - ulpravda.ru
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings - Sahm
Will Celldex Therapeutics Inc. stock attract more institutional investors2025 Market Overview & Precise Swing Trade Alerts - ulpravda.ru
Can Celldex Therapeutics Inc. stock deliver surprise earnings beatStop Loss & Daily Growth Stock Investment Tips - ulpravda.ru
How Celldex Therapeutics Inc. stock trades during market volatility2025 Analyst Calls & Fast Entry Momentum Trade Alerts - ulpravda.ru
Is Celldex Therapeutics Inc. stock a good choice for value investorsMarket Sentiment Summary & Smart Allocation Stock Reports - ulpravda.ru
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company - Barchart.com
Celldex Therapeutics (CLDX) Stock Analysis: Biotechnology Innovator with Over 100% Upside Potential - DirectorsTalk Interviews
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% HigherShould You Buy? - MarketBeat
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9% - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Strong Buy Ratings and Nearly 96% Upside Potential - DirectorsTalk Interviews
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 - Insider Monkey
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely - Yahoo Finance
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX - MarketBeat
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick - Sahm
Income Plays: How sustainable is Celldex Therapeutics Inc. stock dividend payoutGDP Growth & AI Powered Trade Plan Recommendations - Улправда
Will Celldex Therapeutics Inc. stock outperform value stocksJuly 2025 Levels & Weekly High Potential Stock Alerts - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform growth indexesJuly 2025 Spike Watch & Verified Swing Trading Watchlists - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform tech sector in 2025Weekly Trade Summary & Low Volatility Stock Suggestions - Улправда
How Celldex Therapeutics Inc. stock performs after earningsInflation Watch & Stepwise Entry and Exit Trade Signals - Улправда
Aug Summary: Will Celldex Therapeutics Inc. stock see insider buying2025 Momentum Check & Real-Time Buy Signal Alerts - Улправда
Barclays Maintains Celldex Therapeutics (CLDX) Underweight Recommendation - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays - MarketBeat
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Bellevue Group AG Has $67.31 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Eventide Asset Management LLC Lowers Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Redmile Group LLC - MarketBeat
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors? - Sahm
HighVista Strategies LLC Purchases New Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.5%Should You Sell? - MarketBeat
Celldex Therapeutics (CLDX) Valuation After Launching Second Global Phase 3 Program for Barzolvolimab - Sahm
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism - marketscreener.com
Celldex initiates phase 3 trial for cold urticaria and dermographism drug - Investing.com Canada
Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism - TradingView — Track All Markets
Celldex Initiates Global Registrational Phase 3 Program of - GlobeNewswire
19,627 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by Bollard Group LLC - Defense World
Redlands Daily Facts - FinancialContent
Celldex Therapeutics SVP & General Counsel Sells Shares - TradingView — Track All Markets
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month HighHere's Why - MarketBeat
Does Celldex Therapeutics Inc (CLDX) offer a good opportunity for investors? - setenews.com
Celldex Therapeutics stock hits 52-week high at $29.14 By Investing.com - Investing.com Nigeria
How Celldex Therapeutics Inc. (TCE2) stock stacks up against competitorsJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Can Celldex Therapeutics Inc. (TCE2) stock sustain institutional flowsInflation Watch & Consistent Return Investment Signals - Newser
Celldex Therapeutics stock hits 52-week high at $29.14 - Investing.com India
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX - Defense World
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):